These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22149435)

  • 21. Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.
    Smith MR; Kantoff PW
    Semin Oncol; 1995 Dec; 22(6):625-32. PubMed ID: 8539637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
    Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
    J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder cancer: current management and opportunities for a personalized approach.
    Galsky MD; Hall SJ
    Mt Sinai J Med; 2010; 77(6):587-96. PubMed ID: 21105122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on chemotherapy for advanced bladder cancer.
    Rosenberg JE; Carroll PR; Small EJ
    J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New concepts in the management of MIBC in 2010].
    Pignot G; Molinié V; Coloby P; Culine S; Gravis G; Rossi D; Theodore C; Zerbib M
    Prog Urol; 2011 Mar; 21 Suppl 2():S38-42. PubMed ID: 21397826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathology of urinary bladder carcinoma: less common variants.
    Damjanov I; Golubović M
    Srp Arh Celok Lek; 2011; 139(9-10):693-9. PubMed ID: 22070010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coexistent intraurothelial carcinoma and muscle-invasive urothelial carcinoma of the bladder: clonality and somatic down-regulation of DNA mismatch repair.
    Blanes A; Rubio J; Sanchez-Carrillo JJ; Diaz-Cano SJ
    Hum Pathol; 2009 Jul; 40(7):988-97. PubMed ID: 19368958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
    De Santis M; Bachner M
    Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
    Rouprêt M; Guillotreau J; Irani J; Zerbib M
    Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder cancer: translating molecular genetic insights into clinical practice.
    Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
    Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Transitional cell carcinoma involvement of the prostate].
    Bassi P; De Lisa A; Usai P; Pinto F; Sacco E
    Ann Urol (Paris); 2005 Nov; 39 Suppl 5():S113-9. PubMed ID: 16425728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group.
    Dreicer R; Roth B; Wilding G;
    Cancer; 2003 Apr; 97(8 Suppl):2109-14. PubMed ID: 12673703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
    Zhang M; Tao R; Zhang C; Shen Z
    Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Systemic chemotherapy of urothelial cancer].
    Wolff JM; Jakse G
    Urologe A; 1992 May; 31(3):W19-24. PubMed ID: 1615589
    [No Abstract]   [Full Text] [Related]  

  • 40. [Annular constriction of the rectum secondary to urothelial carcinoma of the bladder].
    Ito Y; Nishimoto K; Ogata K; Fujioka T
    Hinyokika Kiyo; 2008 Aug; 54(8):553-5. PubMed ID: 18788446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.